HaemodialysisCOOL HDNCT07377500
Dialysate Cooling for the Preservation of Cognitive Function in People Receiving Haemodialysis
A study testing Dialysis cooling in people with Haemodialysis and Kidney Failure, run by University Hospitals of Derby and Burton NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
When a person's kidneys are not working properly, they need a life-saving treatment called haemodialysis three times a week to filter the waste and extra fluids from the blood. 25 000 adults in the United Kingdom are currently having haemodialysis and unfortunately more than two-thirds of these people experience… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Haemodialysis, Kidney Failure
- What is being tested?
- Dialysis cooling
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 356 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Apr 2026to 1 Jan 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The participant is receiving maintenance in-centre haemodialysis
- Over 18 years of age at time of consent
- The participant is able and willing to provide written informed consent.
Who cannot join
- Participants with confirmed diagnosis of dementia.
- Participants who lack capacity to consent.
- Participants having dialysis less than three times a week.
- Pregnant participants.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site
Royal Derby Hospital
Derby, Derbyshire, DE223DT
Daniel Davis, 07472910392, daniel.davis6@nhs.net
About this study
Official title: Randomised Controlled Trial of Dialysate Cooling for the Preservation of Cognitive Function in People Receiving Haemodialysis
When a person's kidneys are not working properly, they need a life-saving treatment called haemodialysis three times a week to filter the waste and extra fluids from the blood. 25 000 adults in the United Kingdom are currently having haemodialysis and unfortunately more than two-thirds of these people experience problems with thinking and memory, which may lead to dementia. These problems tend to worsen more rapidly than people who are not on haemodialysis. This decline in brain function can make it harder for people to do everyday tasks, increase their reliance on others, and lower their overall quality of life. It also raises the chances of needing hospital care and can shorten their lifespan.
One reason for this decline in thinking and memory could be the dialysis treatment itself. Research has shown that blood flow to the brain can drop during dialysis. If this happens regularly, it can harm the brain over time. Earlier studies found that cooling the dialysis fluid slightly (to 0.5°C below body temperature) helped people tolerate dialysis better and showed less brain damage on magnetic imaging brain scans (MRI) after a year, compared to those who had haemodialysis without cooling the dialysis fluid. However, the investigators still don't know if this brain protection translates into better thinking and memory for people on haemodialysis.
Read more
This study will see if cooling the dialysis fluid helps preserve thinking and memory function.
The investigators will invite participants at three hospitals with haemodialysis centres to take part. Those who agree will be randomly assigned to either standard dialysis or cooled dialysis. The investigators will assess participants' thinking and memory functions using special tests at the start of the study and again after a year. By comparing the results from both groups, the investigators hope to see if the cooled dialysis really helps protect brain.
Read the detailed description
Cognitive impairment is increasingly recognised as a major problem in the 25,000 adults with kidney failure treated by haemodialysis in the United Kingdom. The onset of cognitive impairment happens early after starting haemodialysis, and has an accelerated course so that some degree of cognitive impairment is almost universal, and over two-thirds of patients have moderate to severe reductions on cognitive function testing. A systematic review and meta-analysis of cognition in people on haemodialysis found that their global cognitive function scores were 25% lower than the general population, particularly in the domains of working memory, attention, orientation and executive function. Furthermore, the one-year risk for developing multi-infarct dementia in people on haemodialysis is more than 7 times higher than the general population. Investigators previously studied brain white matter microstructure in haemodialysis patients using diffusion tensor magnetic resonance imaging (MRI) and demonstrated the presence of significant brain white matter damage in haemodialysis patients compared to aged-matched controls. The amount of brain white matter damage correlated with lower score in cognitive function tests. Cognitive impairment in people on haemodialysis is a major component of the frailty syndrome that is also common in this population and cognitive impairment leads to increased dependency, poor quality of life, and reduces the ability of patients to correctly take medications and follow other important aspects of treatment such as dietary and fluid restrictions. Furthermore, cognitive impairment is associated with reduced survival and higher rates of hospitalisation. This has a further detrimental impact on quality of life and results in additional costs to the health service.
Working memory is the ability to hold and manipulate information in mind in the short term, which enables completion of cognitive tasks. It is one of the executive functions and it is well established that these are predictors for ability to carry out activities of daily living such as managing medications and using transport, executive function test performance is a stronger predictor than general cognition for activities and is vital for decision making. Working memory has been suggested as a potential treatment target due to its importance as a predictor of function. Letter Number Sequencing (LNS) is a well established test for working memory, it is derived from the Wechsler Adult Intelligence Scale-III and Wechsler Adult Intelligence Scale-IV test batteries. The LNS has clear face validity as a test of working memory. The participant hears a sequence of letters and numbers and must sort them into separate sequences of letters and numbers in the correct order. Testing working memory using LNS in haemodialysis patients compared to healthy controls demonstrated significant impairment in haemodialysis patients' working memory. Currently there are no interventions proven to protect cognitive function in people on haemodialysis.
Although haemodialysis is life sustaining for those with kidney failure, it is increasingly recognised that the haemodynamic effects of the treatment itself have negative effects on the blood flow to various vascular beds. These effects manifest as intradialytic hypotension, myocardial hypoperfusion leading to myocardial stunning and brain hypoperfusion. Dialysate cooling was first tested as an intervention in the 1980s to reduce intradialytic hypotension. Since then, there has been a large body of evidence that demonstrated beneficial effect of dialysate cooling on blood pressure. Dialysate cooling has been found to improve the stability of blood pressure and reduce intradialytic hypotension, confirmed in two metanalyses.
In smaller studies, dialysate cooling has also been shown to protect against intradialytic cardiac dysfunction and ameliorate myocardial stunning. In a previous NIHR-funded randomised clinical trial, investigators tested the hypothesis that improved haemodynamic stability with dialysate cooling would reduce the development of ischaemic lesions in the brain as determined by diffusion tensor imaging (DTI) MRI. The investigators randomised 73 participants to dialysate cooling to 0.5○C below body temperature or standard dialysis at 37○C. After one-year the standard haemodialysis patients developed MRI changes consistent with ischemic brain injury (increased fractional anisotropy and reduced radial diffusivity), cooled dialysate improved hemodynamic tolerability, and this group were protected against the development of brain white matter changes. The trial was designed with DTI-MRI as the primary outcome measure, and this meant that the study was not powered or designed to assess the effect on cognitive function.
More recently, a large cluster randomised, registry-based pragmatic trial (MyTEMP) conducted in Canada failed to demonstrate that dialysate cooling led to survival benefit or reduction in major cardiovascular events. However methodological limitations, lack of granularity of patient-level data and absence of important patient-centred outcomes mean that these results do not address questions as to whether cooling the dialysate can improve patient-centred outcomes, including protection against the development of cognitive impairment.
OBJECTIVES AND OUTCOME MEASURES/ ENDPOINTS
Haemodialysis causes significant haemodynamic effects, often causing blood pressure drops and leading to reduced perfusion of cardiac and brain tissue. Subclinical ischaemic injury to the brain has therefore been suggested as a mechanism whereby haemodialysis may cause or accelerate cognitive impairment. Investigators previously conducted a randomised controlled trial that examined the effects of cooling the dialysis fluid to 0.5○C below body temperature, a simple intervention that reduces the fall in blood pressure during dialysis. Compared to standard dialysis with dialysis fluid temperature 37○C, this trial demonstrated that dialysate cooling preserved brain white matter microstructure as assessed by MRI. However, this trial was not designed to assess the effect of dialysate cooling on cognitive function and was not powered to do so. Building on this work, investigators now propose to test the hypothesis that cooling the dialysate to 0.5○C below body temperature preserves cognitive function in haemodialysis patients.
This randomised controlled trial will answer the important clinical question of whether dialysate cooling leads to preservation of cognitive function in people on haemodialysis, building upon our previous work showing this intervention preserves brain white matter structural integrity. This is an important patient centred outcome due to the impact of cognitive function on functional status and quality of life.
- Conditions
- Haemodialysis, Kidney Failure
- Being tested
- Dialysis cooling
- Keywords
- DIALYSATE COOLING, KIDNEY FAILURE, HAEMODIALYSIS, COGNITIVE IMPAIRMENT
- Medical subject headings
- Renal Insufficiency, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dialysis coolingOther
dialysis with a dialysate temperature of 0.5 degrees below body temperature for a period of one year.
| Study group | Role | What they receive |
|---|---|---|
| Standard temperature dialysis | No intervention | Dialysis with a dialysate temperature of 37 degrees |
| Cooled dialysis | Active comparator | Dialysis with a dialysate temperature of 0.5 degrees below body temperature. Receives: Other: Dialysis cooling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in working memory
Change in working memory as measured by the Letter Number Sequencing (LNS) test after one year from randomisation.
Measured: One year from randomisation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2026
- Study start1 Apr 2026 (estimated)
- Primary completion1 Oct 2026 (estimated)
- Study completion1 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (26)Papers the sponsor has linked to this study.
- Other trials for HaemodialysisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 356 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Tarek Eldehni, Principal investigator, University of Nottingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07377500
- Sponsor's protocol ID
- UHDB/2024/007
- Other IDs
- 345755
- Acronym
- COOL HD
- Status last verified
- Jan 2026
- First submitted
- 2 Jan 2026
- Last updated
- 3 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Selby NM, McIntyre CW. A systematic review of the clinical effects of reducing dialysate fluid temperature. Nephrol Dial Transplant. 2006 Jul;21(7):1883-98. doi: 10.1093/ndt/gfl126. Epub 2006 Apr 6.
PubMed 16601075Sherman RA, Faustino EF, Bernholc AS, Eisinger RP. Effect of variations in dialysate temperature on blood pressure during hemodialysis. Am J Kidney Dis. 1984 Jul;4(1):66-8. doi: 10.1016/s0272-6386(84)80029-3.
PubMed 6377884Anazodo UC, Wong DY, Theberge J, Dacey M, Gomes J, Penny JD, van Ginkel M, Poirier SE, McIntyre CW. Hemodialysis-Related Acute Brain Injury Demonstrated by Application of Intradialytic Magnetic Resonance Imaging and Spectroscopy. J Am Soc Nephrol. 2023 Jun 1;34(6):1090-1104. doi: 10.1681/ASN.0000000000000105. Epub 2023 Mar 9.
PubMed 36890644Findlay MD, Dawson J, Dickie DA, Forbes KP, McGlynn D, Quinn T, Mark PB. Investigating the Relationship between Cerebral Blood Flow and Cognitive Function in Hemodialysis Patients. J Am Soc Nephrol. 2019 Jan;30(1):147-158. doi: 10.1681/ASN.2018050462. Epub 2018 Dec 7.
PubMed 30530658Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Siriopol D, Covic A, Basile C, Ortiz A. An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. Clin Kidney J. 2020 Jul 8;13(6):981-993. doi: 10.1093/ckj/sfaa078. eCollection 2020 Dec.
PubMed 33391741Assa S, Hummel YM, Voors AA, Kuipers J, Westerhuis R, de Jong PE, Franssen CF. Hemodialysis-induced regional left ventricular systolic dysfunction: prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol. 2012 Oct;7(10):1615-23. doi: 10.2215/CJN.00850112. Epub 2012 Jul 19.
PubMed 22822014Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009 May;4(5):914-20. doi: 10.2215/CJN.03900808. Epub 2009 Apr 8.
PubMed 19357245McIntyre CW. Recurrent circulatory stress: the dark side of dialysis. Semin Dial. 2010 Sep-Oct;23(5):449-51. doi: 10.1111/j.1525-139X.2010.00782.x.
PubMed 21039872Sanchez-Fernandez MDM, Reyes Del Paso GA, Gil-Cunquero JM, Fernandez-Serrano MJ. Executive function in end-stage renal disease: Acute effects of hemodialysis and associations with clinical factors. PLoS One. 2018 Sep 4;13(9):e0203424. doi: 10.1371/journal.pone.0203424. eCollection 2018.
PubMed 30180208Berger I, Wu S, Masson P, Kelly PJ, Duthie FA, Whiteley W, Parker D, Gillespie D, Webster AC. Cognition in chronic kidney disease: a systematic review and meta-analysis. BMC Med. 2016 Dec 14;14(1):206. doi: 10.1186/s12916-016-0745-9.
PubMed 27964726Brodski J, Rossell SL, Castle DJ, Tan EJ. A Systematic Review of Cognitive Impairments Associated With Kidney Failure in Adults Before Natural Age-Related Changes. J Int Neuropsychol Soc. 2019 Jan;25(1):101-114. doi: 10.1017/S1355617718000917. Epub 2018 Nov 22.
PubMed 30463631Gaubert F, Borg C, Chainay H. Decision-Making in Alzheimer's Disease: The Role of Working Memory and Executive Functions in the Iowa Gambling Task and in Tasks Inspired by Everyday Situations. J Alzheimers Dis. 2022;90(4):1793-1815. doi: 10.3233/JAD-220581.
PubMed 36336931McDougall GJ, Han A, Staggs VS, Johnson DK, McDowd JM. Predictors of instrumental activities of daily living in community-dwelling older adults. Arch Psychiatr Nurs. 2019 Oct;33(5):43-50. doi: 10.1016/j.apnu.2019.08.006. Epub 2019 Aug 20.
PubMed 31711593Baddeley A. Working memory. Science. 1992 Jan 31;255(5044):556-9. doi: 10.1126/science.1736359.
PubMed 1736359Joshi U, Subedi R, Poudel P, Ghimire PR, Panta S, Sigdel MR. Assessment of quality of life in patients undergoing hemodialysis using WHOQOL-BREF questionnaire: a multicenter study. Int J Nephrol Renovasc Dis. 2017 Jul 19;10:195-203. doi: 10.2147/IJNRD.S136522. eCollection 2017.
PubMed 28790861
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomised Controlled Trial of Dialysate Cooling for the Preservation of Cognitive Function in People Receiving Haemodialysis
- ClinicalTrials.gov ID
- NCT07377500
- Acronym / sponsor ID
- COOL HD / UHDB/2024/007
- Conditions
- Haemodialysis, Kidney Failure
- Keywords
- DIALYSATE COOLING, KIDNEY FAILURE, HAEMODIALYSIS, COGNITIVE IMPAIRMENT
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 356 participants (estimated)
- Lead sponsor
- University Hospitals of Derby and Burton NHS Foundation TrustUniversity, hospital or other
- Study start
- 1 Apr 2026 (estimated)
- Primary completion
- 1 Oct 2026 (estimated)
- Study completion
- 1 Jan 2028 (estimated)
- First posted
- 30 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
When a person's kidneys are not working properly, they need a life-saving treatment called haemodialysis three times a week to filter the waste and extra fluids from the blood. 25 000 adults in the United Kingdom are currently having haemodialysis and unfortunately more than two-thirds of these people experience problems with thinking and memory, which may lead to dementia. These problems tend to worsen more rapidly than people who are not on haemodialysis. This decline in brain function can make it harder for people to do everyday tasks, increase their reliance on others, and lower their overall quality of life. It also raises the chances of needing hospital care and can shorten their lifespan.
One reason for this decline in thinking and memory could be the dialysis treatment itself. Research has shown that blood flow to the brain can drop during dialysis. If this happens regularly, it can harm the brain over time. Earlier studies found that cooling the dialysis fluid slightly (to 0.5°C below body temperature) helped people tolerate dialysis better and showed less brain damage on magnetic imaging brain scans (MRI) after a year, compared to those who had haemodialysis without cooling the dialysis fluid. However, the investigators still don't know if this brain protection translates into better thinking and memory for people on haemodialysis.
This study will see if cooling the dialysis fluid helps preserve thinking and memory function.
The investigators will invite participants at three hospitals with haemodialysis centres to take part. Those who agree will be randomly assigned to either standard dialysis or cooled dialysis. The investigators will assess participants' thinking and memory functions using special tests at the start of the study and again after a year. By comparing the results from both groups, the investigators hope to see if the cooled dialysis really helps protect brain.
Detailed description
Cognitive impairment is increasingly recognised as a major problem in the 25,000 adults with kidney failure treated by haemodialysis in the United Kingdom. The onset of cognitive impairment happens early after starting haemodialysis, and has an accelerated course so that some degree of cognitive impairment is almost universal, and over two-thirds of patients have moderate to severe reductions on cognitive function testing. A systematic review and meta-analysis of cognition in people on haemodialysis found that their global cognitive function scores were 25% lower than the general population, particularly in the domains of working memory, attention, orientation and executive function. Furthermore, the one-year risk for developing multi-infarct dementia in people on haemodialysis is more than 7 times higher than the general population. Investigators previously studied brain white matter microstructure in haemodialysis patients using diffusion tensor magnetic resonance imaging (MRI) and demonstrated the presence of significant brain white matter damage in haemodialysis patients compared to aged-matched controls. The amount of brain white matter damage correlated with lower score in cognitive function tests. Cognitive impairment in people on haemodialysis is a major component of the frailty syndrome that is also common in this population and cognitive impairment leads to increased dependency, poor quality of life, and reduces the ability of patients to correctly take medications and follow other important aspects of treatment such as dietary and fluid restrictions. Furthermore, cognitive impairment is associated with reduced survival and higher rates of hospitalisation. This has a further detrimental impact on quality of life and results in additional costs to the health service.
Working memory is the ability to hold and manipulate information in mind in the short term, which enables completion of cognitive tasks. It is one of the executive functions and it is well established that these are predictors for ability to carry out activities of daily living such as managing medications and using transport, executive function test performance is a stronger predictor than general cognition for activities and is vital for decision making. Working memory has been suggested as a potential treatment target due to its importance as a predictor of function. Letter Number Sequencing (LNS) is a well established test for working memory, it is derived from the Wechsler Adult Intelligence Scale-III and Wechsler Adult Intelligence Scale-IV test batteries. The LNS has clear face validity as a test of working memory. The participant hears a sequence of letters and numbers and must sort them into separate sequences of letters and numbers in the correct order. Testing working memory using LNS in haemodialysis patients compared to healthy controls demonstrated significant impairment in haemodialysis patients' working memory. Currently there are no interventions proven to protect cognitive function in people on haemodialysis.
Although haemodialysis is life sustaining for those with kidney failure, it is increasingly recognised that the haemodynamic effects of the treatment itself have negative effects on the blood flow to various vascular beds. These effects manifest as intradialytic hypotension, myocardial hypoperfusion leading to myocardial stunning and brain hypoperfusion. Dialysate cooling was first tested as an intervention in the 1980s to reduce intradialytic hypotension. Since then, there has been a large body of evidence that demonstrated beneficial effect of dialysate cooling on blood pressure. Dialysate cooling has been found to improve the stability of blood pressure and reduce intradialytic hypotension, confirmed in two metanalyses.
In smaller studies, dialysate cooling has also been shown to protect against intradialytic cardiac dysfunction and ameliorate myocardial stunning. In a previous NIHR-funded randomised clinical trial, investigators tested the hypothesis that improved haemodynamic stability with dialysate cooling would reduce the development of ischaemic lesions in the brain as determined by diffusion tensor imaging (DTI) MRI. The investigators randomised 73 participants to dialysate cooling to 0.5○C below body temperature or standard dialysis at 37○C. After one-year the standard haemodialysis patients developed MRI changes consistent with ischemic brain injury (increased fractional anisotropy and reduced radial diffusivity), cooled dialysate improved hemodynamic tolerability, and this group were protected against the development of brain white matter changes. The trial was designed with DTI-MRI as the primary outcome measure, and this meant that the study was not powered or designed to assess the effect on cognitive function.
More recently, a large cluster randomised, registry-based pragmatic trial (MyTEMP) conducted in Canada failed to demonstrate that dialysate cooling led to survival benefit or reduction in major cardiovascular events. However methodological limitations, lack of granularity of patient-level data and absence of important patient-centred outcomes mean that these results do not address questions as to whether cooling the dialysate can improve patient-centred outcomes, including protection against the development of cognitive impairment.
OBJECTIVES AND OUTCOME MEASURES/ ENDPOINTS
Haemodialysis causes significant haemodynamic effects, often causing blood pressure drops and leading to reduced perfusion of cardiac and brain tissue. Subclinical ischaemic injury to the brain has therefore been suggested as a mechanism whereby haemodialysis may cause or accelerate cognitive impairment. Investigators previously conducted a randomised controlled trial that examined the effects of cooling the dialysis fluid to 0.5○C below body temperature, a simple intervention that reduces the fall in blood pressure during dialysis. Compared to standard dialysis with dialysis fluid temperature 37○C, this trial demonstrated that dialysate cooling preserved brain white matter microstructure as assessed by MRI. However, this trial was not designed to assess the effect of dialysate cooling on cognitive function and was not powered to do so. Building on this work, investigators now propose to test the hypothesis that cooling the dialysate to 0.5○C below body temperature preserves cognitive function in haemodialysis patients.
This randomised controlled trial will answer the important clinical question of whether dialysate cooling leads to preservation of cognitive function in people on haemodialysis, building upon our previous work showing this intervention preserves brain white matter structural integrity. This is an important patient centred outcome due to the impact of cognitive function on functional status and quality of life.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard temperature dialysis | No intervention | –Dialysis with a dialysate temperature of 37 degrees |
| Cooled dialysis | Active comparator | Other: Dialysis coolingDialysis with a dialysate temperature of 0.5 degrees below body temperature. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- The participant is receiving maintenance in-centre haemodialysis
- Over 18 years of age at time of consent
- The participant is able and willing to provide written informed consent.
Key exclusion criteria (4 listed)
- Participants with confirmed diagnosis of dementia.
- Participants who lack capacity to consent.
- Participants having dialysis less than three times a week.
- Pregnant participants.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dialysis coolingdialysis with a dialysate temperature of 0.5 degrees below body temperature for a period of one year. | Other | Cooled dialysis |
Primary outcome
Change in working memory
Time frame: One year from randomisation
Change in working memory as measured by the Letter Number Sequencing (LNS) test after one year from randomisation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2026.
- Background: PubMed 16601075Selby NM, McIntyre CW. A systematic review of the clinical effects of reducing dialysate fluid temperature. Nephrol Dial Transplant. 2006 Jul;21(7):1883-98. doi: 10.1093/ndt/gfl126. Epub 2006 Apr 6.
- Background: PubMed 6377884Sherman RA, Faustino EF, Bernholc AS, Eisinger RP. Effect of variations in dialysate temperature on blood pressure during hemodialysis. Am J Kidney Dis. 1984 Jul;4(1):66-8. doi: 10.1016/s0272-6386(84)80029-3.
- Background: PubMed 36890644Anazodo UC, Wong DY, Theberge J, Dacey M, Gomes J, Penny JD, van Ginkel M, Poirier SE, McIntyre CW. Hemodialysis-Related Acute Brain Injury Demonstrated by Application of Intradialytic Magnetic Resonance Imaging and Spectroscopy. J Am Soc Nephrol. 2023 Jun 1;34(6):1090-1104. doi: 10.1681/ASN.0000000000000105. Epub 2023 Mar 9.
- Background: PubMed 30530658Findlay MD, Dawson J, Dickie DA, Forbes KP, McGlynn D, Quinn T, Mark PB. Investigating the Relationship between Cerebral Blood Flow and Cognitive Function in Hemodialysis Patients. J Am Soc Nephrol. 2019 Jan;30(1):147-158. doi: 10.1681/ASN.2018050462. Epub 2018 Dec 7.
- Background: PubMed 33391741Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Siriopol D, Covic A, Basile C, Ortiz A. An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. Clin Kidney J. 2020 Jul 8;13(6):981-993. doi: 10.1093/ckj/sfaa078. eCollection 2020 Dec.
- Background: PubMed 22822014Assa S, Hummel YM, Voors AA, Kuipers J, Westerhuis R, de Jong PE, Franssen CF. Hemodialysis-induced regional left ventricular systolic dysfunction: prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol. 2012 Oct;7(10):1615-23. doi: 10.2215/CJN.00850112. Epub 2012 Jul 19.
- Background: PubMed 19357245Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009 May;4(5):914-20. doi: 10.2215/CJN.03900808. Epub 2009 Apr 8.
- Background: PubMed 21039872McIntyre CW. Recurrent circulatory stress: the dark side of dialysis. Semin Dial. 2010 Sep-Oct;23(5):449-51. doi: 10.1111/j.1525-139X.2010.00782.x.
- Background: PubMed 30180208Sanchez-Fernandez MDM, Reyes Del Paso GA, Gil-Cunquero JM, Fernandez-Serrano MJ. Executive function in end-stage renal disease: Acute effects of hemodialysis and associations with clinical factors. PLoS One. 2018 Sep 4;13(9):e0203424. doi: 10.1371/journal.pone.0203424. eCollection 2018.
- Background: PubMed 27964726Berger I, Wu S, Masson P, Kelly PJ, Duthie FA, Whiteley W, Parker D, Gillespie D, Webster AC. Cognition in chronic kidney disease: a systematic review and meta-analysis. BMC Med. 2016 Dec 14;14(1):206. doi: 10.1186/s12916-016-0745-9.
- Background: PubMed 30463631Brodski J, Rossell SL, Castle DJ, Tan EJ. A Systematic Review of Cognitive Impairments Associated With Kidney Failure in Adults Before Natural Age-Related Changes. J Int Neuropsychol Soc. 2019 Jan;25(1):101-114. doi: 10.1017/S1355617718000917. Epub 2018 Nov 22.
- Background: PubMed 36336931Gaubert F, Borg C, Chainay H. Decision-Making in Alzheimer's Disease: The Role of Working Memory and Executive Functions in the Iowa Gambling Task and in Tasks Inspired by Everyday Situations. J Alzheimers Dis. 2022;90(4):1793-1815. doi: 10.3233/JAD-220581.
- Individual participant dataSharing planned: No
Related trials for Haemodialysis
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
RecruitingPhase 1
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
End Stage Renal Disease on Dialysis, Adult
Not yet recruitingPhase 1/2
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
End Stage Renal Disease, Fatigue
Active, not recruiting
Group Exercise Program Supported By Audiovisual Media During Hemodialysis
Chronic Kidney Failure, Hemodialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tarek Eldehni principal investigator
University of Nottingham
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dialysis cooling in people with Haemodialysis and Kidney Failure, run by University Hospitals of Derby and Burton NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Daniel Davis (07472910392, daniel.davis6@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in working memory (time frame: One year from randomisation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07377500, which also lists 26 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2026.